In 2023, the Chinese Society of Clinical Oncology (CSCO) guidelines recommended PD-1 inhibitors as the first-line treatment for locally advanced and/or metastatic GC, based on the encouraging results from recent clinical evidence and the outcomes of phase III trials (4–6). The gene discussed is PDCD1; the disease is gastric cancer.